23491-49-8

Basic information

• Product Name: 1,2-BenzenediaMine, 4-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-
• Synonyms: 1,2-BenzenediaMine, 4-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-;1,2-BenzenediaMine, 4-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-10;4-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)benzene-1,2-diamine;4-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-1,2-benzenediamine;4-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]benzene-1,2-diamine
• CAS NO: 23491-49-8
• Molecular Formula: C₁₈H₂₂N₆
• Molecular Weight: 322.40748
• Mol File: 23491-49-8.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2-BenzenediaMine, 4-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-BenzenediaMine, 4-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-(23491-49-8)
• EPA Substance Registry System: 1,2-BenzenediaMine, 4-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-(23491-49-8)

Safety Data

• Hazardous Substances Data: 23491-49-8(Hazardous Substances Data)

Usage

General Description

1,2-Benzenediamine, 4-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-, also known as LYNPARZA, is a chemical compound used in pharmaceuticals. It is a poly (ADP-ribose) polymerase (PARP) inhibitor, which means it works by blocking enzymes involved in repairing damaged DNA, leading to the death of cancer cells. LYNPARZA is used as a treatment for ovarian, fallopian tube, and primary peritoneal cancer in patients with specific mutations in their BRCA genes. It is also being investigated for use in other types of cancer and as a potential treatment for other conditions related to DNA repair mechanisms.

Upstream product

• 23623-05-4 4-<5'-(4''-methylpiperazin-1''-yl)benzimidazol-2'-yl>-2-nitroaniline 
• 165596-29-2 ethyl 4-amino-3-nitrobenzenecarboximidate 
• 54998-08-2 4-(4-methylpiperazino)-1,2-diaminobenzene 
• 6393-40-4 4-Amino 3-nitro-benzonitrile 
• 23491-48-7 5-(4-methylpiperazine-1-yl)-2-nitroaniline 
• 29289-18-7 N-(4-cyano-2-nitrophenyl)acetamide 
• 35704-19-9 N-(4-cyanophenyl)acetamide 
• 873-74-5 4-Aminobenzonitrile 
• 109-01-3 1-methyl-piperazine 
• 1635-61-6 5-chloro-2-nitroaniline 
• 23623-05-4 4-[5'-(4'-methylpiperazin-1'-yl)benzimidazol-2'-yl]-2-nitroaniline 
• 184033-32-7 4-cyano-2-nitrotrifluoroacetanilide 
• 51818-98-5 4-acetamido-3-nitrobenzaldehyde 
• 308362-09-6 2-(4-acetamido-3-nitrophenyl)-5-(4-methylpiperazinyl)-1H-benzimidazole 

Downstream Products

• 23555-02-4 4-nitro-1-<5'-<5''-(4'''-methylpiperazin-1'''-yl)benzimidazol-2''-yl>benzimidazol-2'-yl>benzene 
• 179749-11-2 2,2,2-Trifluoro-N-(2-{4-[5-(4-methyl-piperazin-1-yl)-1H,1'H-[2,5']bibenzoimidazolyl-2'-yl]-phenoxy}-ethyl)-acetamide 
• 258843-62-8 4-(3-(6-(4-methylpiperazin-1-yl)-1H,3′H-[2,5′-bibenzo[d]imidazol]-2′-yl)phenoxy)butanoic acid 
• 1419846-73-3 C₅₉H₅₈N₈O₄ 
• 1419846-65-3 C₃₈H₄₀N₈O₂ 
• 1419846-42-6 C₃₉H₂₇F₅N₈O₂ 
• 1419846-34-6 C₃₃H₂₈N₈O₂ 
• 1419846-26-6 C₃₄H₃₀N₈O₂ 

Relevant articles and documents

Di-(benzimidazole)-1, 2, 3-triazole derivative as well as preparation and application thereof in inflammatory dermatosis

The invention belongs to the technical field of drug small molecules, and particularly discloses a brand-new di-(benzimidazole)-1, 2, 3-triazole derivative as well as preparation and application of the brand-new di-(benzimidazole)-1, 2, 3-triazole derivative. The research finds that the brand new compound has an excellent drug effect and low toxic and side effects on the aspect of inflammatory dermatosis, and has a good application prospect in the aspect of drug development of the inflammatory dermatosis.

Design and synthesis of new benzimidazole-carbazole conjugates for the stabilization of human telomeric DNA, telomerase inhibition, and their selective action on cancer cells

Cell-permeable small molecules that enhance the stability of the G-quadruplex (G4) DNA structures are currently among the most intensively pursued ligands for inhibition of the telomerase activity. Herein we report the design and syntheses of four novel benzimidazole-carbazole conjugates and demonstrate their high binding affinity to G4 DNA. S1 nuclease assay confirmed the ligand mediated G-quadruplex DNA protection. Additional evidence from Telomeric Repeat Amplification Protocol (TRAP-LIG) assay demonstrated efficient telomerase inhibition activity by the ligands. Two of the ligands showed IC 50 values in the sub-micromolar range in the TRAP-LIG assay, which are the best among the benzimidazole derivatives reported so far. The ligands also exhibited cancer cell selective nuclear internalization, nuclear condensation, fragmentation, and eventually antiproliferative activity in long-term cell viability assays. Annexin V-FITC/PI staining assays confirm that the cell death induced by the ligands follows an apoptotic pathway. An insight into the mode of ligand binding was obtained from the molecular dynamics simulations.

Radioprotectors

A compound of the formula (Ib): wherein X is NCH3, Y is N, Z is N, R3 is N(CH3)2, and (a) R1 is CH3, R2, R4 and R5 to R11 are hydrogen or (b) R5 is CH3 and R1, R2, R4 and R6 to R11 are hydrogen, and salts and tautomers thereof.